Ken Griffin Ventyx Biosciences, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$1.85 - $3.2 $51,985 - $89,920	-28,100 Reduced 42.58%	37,900 $82,000
Q2 2024 Aug 14, 2024	BUY	$2.31 - $5.59 $44,352 - $107,328	19,200 Added 41.03%	66,000 $152,000
Q1 2024 May 15, 2024	SELL	$1.9 - $10.13 $75,810 - $404,187	-39,900 Reduced 46.02%	46,800 $257,000
Q4 2023 Feb 14, 2024	BUY	$2.08 - $31.18 $158,080 - $2.37 Million	76,000 Added 710.28%	86,700 $214,000
Q3 2023 Nov 14, 2023	SELL	$29.8 - $40.3 $14,900 - $20,150	-500 Reduced 4.46%	10,700 $371,000
Q2 2023 Aug 14, 2023	BUY	$28.53 - $39.55 $159,768 - $221,479	5,600 Added 100.0%	11,200 $367,000
Q1 2023 May 15, 2023	BUY	$29.51 - $46.65 $120,991 - $191,265	4,100 Added 273.33%	5,600 $187,000
Q4 2022 Feb 14, 2023	SELL	$24.16 - $36.38 $521,856 - $785,808	-21,600 Reduced 93.51%	1,500 $49,000
Q3 2022 Nov 14, 2022	BUY	$12.64 - $38.7 $291,984 - $893,970	23,100 New	23,100 $806,000

125

52.9M

35.3K

83K

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $106M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.